Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Avoid Marks Electrical Group (MRK) by Steve Moore in ShareProphets
- Avoid THG (THG) by Steve Moore in ShareProphets
- Buy Water Intelligence (WATR) by Hot Stock Rockets in ShareProphets
- Avoid Headlam Group (HEAD) by Steve Moore in ShareProphets
- Avoid Pinewood Technologies Group (PINE) by Steve Moore in ShareProphets
- Buy Abrdn (ABDN) by Tom Winnifrith in ShareProphets
- Buy Abrdn (ABDN) by Steve Moore in ShareProphets
- Buy Capital Limited (DI) (CAPD) by Hot Stock Rockets in ShareProphets
- Avoid Aptamer Group (APTA) by Steve Moore in ShareProphets
- Hold S4 Capital (SFOR) by Deutsche Bank
- Buy Ecora Resources (ECOR) by Berenberg
- Hold Kenmare Resources (CDI) (KMR) by Berenberg
- Buy Luceco (LUCE) by Deutsche Bank
- Outperform Ecora Resources (ECOR) by RBC Capital
- Buy BAE Systems (BA.) by Bank of America
- Hold Reckitt Benckiser Group (RKT) by Deutsche Bank
- Neutral Bellway (BWY) by Goldman Sachs
- Buy BP (BP.) by Goldman Sachs
- Buy HSBC Holdings (HSBA) by Goldman Sachs
- Hold RS Group (RS1) by Berenberg
Shield Therapeutics (STX) Share Price
Health Care Sector
NOTE: This is based on 61 open tips for Shield Therapeutics (STX)
| Latest Bid : 7.90p | Latest Ask : 8.10p |
| High Today : 8.30p | Low Today : 7.38p |
| This Years High : 12.20p | This Years Low : 2.26p |
| Volume : 5,829,606 | MKT Cap : £62.56M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Shield Therapeutics (STX) Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.Shield Therapeutics (STX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Peel Hunt | Premium Only | 2025-11-07 16:31:00 07/11/2025 | 16.79% |
| Buy | Peel Hunt | Premium Only | 2025-09-15 11:19:00 15/09/2025 | -2.44% |
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | -175.86% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | 4.58% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | 40.85% |
Shield Therapeutics (STX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 7.90p | Latest Ask : 8.10p |
| High Today : 8.30p | Low Today : 7.38p |
| This Years High : 12.20p | This Years Low : 2.26p |
| Volume : 5,829,606 | MKT Cap : £62.56M |
Shield Therapeutics Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Shield Therapeutics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Peel Hunt | Premium Only | 2025-11-07 16:31:00 07/11/2025 | 16.79% |
| Buy | Peel Hunt | Premium Only | 2025-09-15 11:19:00 15/09/2025 | -2.44% |
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | -175.86% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | 4.58% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | 40.85% |